CanSino Biologics (HKSE:06185) Interest Expense : HK$-73.2 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CanSino Biologics's interest expense for the three months ended in Dec. 2024 was HK$ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-73.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CanSino Biologics's Operating Income for the three months ended in Dec. 2024 was HK$ 0.0 Mil. CanSino Biologics's Interest Expense for the three months ended in Dec. 2024 was HK$ 0.0 Mil. GuruFocus does not calculate CanSino Biologics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CanSino Biologics Interest Expense Historical Data

The historical data trend for CanSino Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Interest Expense Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.17

-25.00

-46.17

-70.16

-64.04

CanSino Biologics Quarterly Data
	Dec16	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial														-17.90	-19.89	-15.94	-19.43	-

CanSino Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-73.2 Mil.

CanSino Biologics (HKSE:06185) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CanSino Biologics's Interest Expense for the three months ended in Dec. 2024 was HK$0.0 Mil. Its Operating Income for the three months ended in Dec. 2024 was HK$0.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was HK$1,186.4 Mil.

CanSino Biologics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate CanSino Biologics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

CanSino Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Interest Expense

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

Executives

Yu Xuefeng	2501 Other
Chao Shou Bai	2202 Interest of your spouse
Mao Helen Huihua	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Zhu Tao
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics Headlines

No Headlines